Salarius Pharmaceuticals, Inc. — Director's Dealing 2020

Mar 25, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Salarius Pharmaceuticals, Inc. (SLRX)
CIK: 0001615219
Period of Report: 2020-03-23

Reporting Person: Arthur David J. (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-23	Stock Option (right to buy)	$0.61	A	60000	Acquired	2030-03-22	Common Stock (60000.0)	Direct

Footnotes

F1: 25% of the options granted are fully vested on March 23, 2021, and quarterly vesting of the remaining options over 3 years.